Methods of treating neurological conditions with hematopoeitic growth factors
The present invention relates to a method of treating a neurological condition in a mammal by administering at least one hematopoietic growth factor.
1. A method of treating glaucoma in a mammal, consisting of administering to the mammal in need thereof, hematopoietic factor selected from the group consisting of mammalian granulocyte-colony stimulating factor (G-CSF), human G-CSF, a protein having at least 90% homology to SEQ ID NO:37, a protein having at least 90% homology to SEQ ID NO:38, a protein having at least 90% homology to SEQ ID NO:39 PEG-modified G-CSF or a combination thereof, optionally present with at least one pharmaceutically acceptable carrier, in an amount sufficient to treat the glaucoma.
2. The method of claim 1 , wherein the hematopoietic factor is a human factor or derived from a human factor.
3. The method of claim 1 , wherein the mammal is human.
4. The method of claim 1 , wherein the hematopoietic factor is administered by one or more modes of administration selected from the group consisting of topically, intravenously, and subcutaneously.
5. The method of claim 1 , wherein mammalian G-CSF is administered.
6. The method of claim 1 , wherein human G-CSF is administered.
7. The method of claim 1 , wherein a protein having at least 90% homology to SEQ ID NO:37 is administered.
8. The method of claim 1 , wherein a protein having at least 90% homology to SEQ ID NO:38 is administered.
9. The method of claim 1 , wherein a protein having at least 90% homology to SEQ ID NO:39 is administered.
10. The method of claim 1 , wherein the glaucoma is primary open-angle glaucoma; normal tension glaucoma; angle-closure glaucoma; acute glaucoma; pigmentary glaucoma; exfoliation syndrome or trauma-related glaucoma.